Nagase Takeshi, Kanai Toshio, Nakagawa Motohito, Kumamoto Yusuke, Imai Syun, Wada Osamu, Honda Tomo, Hoshino Go, Atsukawa Kazuhiro, Sakaguchi Takashi, Shiba Tadahiko, Nonaka Takashi, Imajyo Kento, Ogawa Yuji
Dept. of Surgery, Hiratsuka City Hospital.
Gan To Kagaku Ryoho. 2010 Nov;37(11):2177-9.
We analyzed the clinical efficacy of pre-operative combination chemotherapy using docetaxel, cisplatin and S-1 for advanced gastric cancer. Four patients were enrolled and staging laparoscopy was performed. Patients received intravenous docetaxel and cisplatin (35 mg/m2) on day 1 and 15, and oral S-1 80 mg/m2 on day 1-14 every 4 weeks. Two patients received two courses of chemotherapy and two patients received three courses of chemotherapy. Neutropenia of more than grade 3 was found in 3 cases. All cases were PR on preoperative imaging. Curative operation was performed on three cases. Histological anti-tumor effect was judged to be grade 2 in 1 case and grade 1a in 3 cases. In the postoperative period, all patients received S-1-based adjuvant chemotherapy. The combination chemotherapy using docetaxel, cisplatin and S-1 plus operation was a candidate for the standard treatment strategy for advanced gastric cancer.
我们分析了多西他赛、顺铂和S-1术前联合化疗对晚期胃癌的临床疗效。纳入4例患者并进行分期腹腔镜检查。患者每4周在第1天和第15天接受静脉注射多西他赛和顺铂（35mg/m²），并在第1-14天口服S-1 80mg/m²。2例患者接受了两个疗程的化疗，2例患者接受了三个疗程的化疗。3例出现3级以上中性粒细胞减少。所有病例术前影像学检查均为PR。3例患者接受了根治性手术。组织学抗肿瘤效果判断为1例2级、3例1a级。术后，所有患者均接受了以S-1为基础的辅助化疗。多西他赛、顺铂和S-1联合化疗加手术是晚期胃癌标准治疗策略的候选方案。
